HA
CRSP icon

HC Advisors’s CRISPR Therapeutics CRSP Stock Holding History

HC Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-3,913
Closed -$254K – 62
2025
Q3 		$254K Sell
3,913
-305
-7% -$17.5K 0.18% 49
2025
Q2 		$205K Buy
+4,218
New +$163K 0.14% 55
2024
Q4 		– Sell
-4,319
Closed -$203K – 62
2024
Q3 		$203K Buy
4,319
+134
+3% +$6.8K 0.17% 48
2024
Q2 		$226K Sell
4,185
-280
-6% -$16.2K 0.21% 44
2024
Q1 		$304K Buy
4,465
+158
+4% +$11.3K 0.15% 74
2023
Q4 		$270K Buy
+4,307
New +$238K 0.15% 75
2023
Q3 		– Sell
-4,008
Closed -$225K – 86
2023
Q2 		$225K Sell
4,008
-671
-14% -$38.1K 0.13% 73
2023
Q1 		$212K Sell
4,679
-622
-12% -$30.2K 0.13% 76
2022
Q4 		$215K Sell
5,301
-48,643
-90% -$2.58M 0.15% 74
2022
Q3 		$3.52M Buy
53,944
+46,512
+626% +$3.37M 2.43% 12
2022
Q2 		$452K Buy
7,432
+154
+2% +$9.05K 0.32% 49
2022
Q1 		$457K Sell
7,278
-1,211
-14% -$76K 0.29% 47
2021
Q4 		$643K Buy
8,489
+2,739
+48% +$239K 0.39% 39
2021
Q3 		$644K Buy
5,750
+43
+0.8% +$5.4K 0.42% 36
2021
Q2 		$924K Buy
5,707
+1,077
+23% +$131K 0.57% 32
2021
Q1 		$564K Buy
4,630
+412
+10% +$62.2K 0.36% 39
2020
Q4 		$646K Buy
4,218
+388
+10% +$45.9K 0.44% 38
2020
Q3 		$320K Buy
3,830
+173
+5% +$15.3K 0.26% 49
2020
Q2 		$269K Buy
+3,657
New +$214K 0.22% 64

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
GP
GSK plc London $599M AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

HC Advisors's CRSP Position: Q4 2025 in Review

HC Advisors sold out of CRISPR Therapeutics (CRSP) in Q4 2025, closing a stake of 3,913 shares — an estimated $254K sold.

HC Advisors first reported a position in CRSP in Q2 2020 and held it in 19 quarters. The position peaked at $3.52M in Q3 2022. 479 funds tracked by Wall St. Rank hold CRSP as of Q4 2025.

  • HC Advisors reported no remaining CRISPR Therapeutics position as of Q4 2025 after selling out during the quarter.
  • HC Advisors sold 3,913 CRISPR Therapeutics shares in Q4 2025, an estimated $254K.
  • HC Advisors first reported a position in CRISPR Therapeutics in Q2 2020 and held it in 19 quarters.
  • HC Advisors's CRISPR Therapeutics position peaked at $3.52M in Q3 2022.
  • 479 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2025.

Based on HC Advisors's 13F filing for Q4 2025, filed 11 Feb 2026.